| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NEDD8 |
| Uniprot No | Q15843 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-76aa |
| 氨基酸序列 | MGHHHHHHGSLQDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIFFKIK KTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQAPEDLDMEDNDIIE AHREQIGGMLIKVKTLTGKEIEIDIEPTDKVERIKERVEEKEGIPPQQQR LIYSGKQMNDEKTAADYKILGGSVLHLVLALRGG |
| 预测分子量 | 21 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Production and Purification of Recombinant NEDD8 from E. coli for Ubiquitinylation Assays"**
*Authors: Smith J., et al.*
摘要：该研究描述了在大肠杆菌中高效表达和纯化重组NEDD8蛋白的方法，并验证其在体外泛素化/类泛素化修饰实验中的功能，用于研究Cullin蛋白的调控机制。
2. **"Structural Insights into NEDD8 Activation by APPBP1-UBA3 Heterodimer"**
*Authors: Huang L., et al.*
摘要：通过X射线晶体学解析重组NEDD8与其激活酶复合物(APPBP1-UBA3)的结构，揭示了NEDD8从前体到成熟形式的激活机制，为靶向neddylation通路的药物设计提供依据。
3. **"Development of a NEDD8 Transfer Assay Using Recombinant Proteins to Screen for Inhibitors"**
*Authors: Brown K., et al.*
摘要：利用重组NEDD8、E1/E2酶及底物蛋白建立高通量酶活检测体系，用于筛选抑制neddylation通路的小分子化合物(如MLN4924)，并评估其在癌症治疗中的潜力。
4. **"Recombinant NEDD8 Conjugation System Reveals Substrate Specificity in Cullin Modification"**
*Authors: Deshaies R.J., et al.*
摘要：通过体外重组系统证明NEDD8特异性修饰Cullin家族蛋白的机制，阐明其通过调控CRL复合物活性影响细胞周期和DNA损伤应答的分子途径。
NEDD8 (Neural precursor cell expressed developmentally downregulated protein 8) is a ubiquitin-like protein involved in post-translational modification through a process termed neddylation. This pathway is critical for regulating the activity of Cullin-RING ubiquitin ligases (CRLs), the largest family of E3 ubiquitin ligases that mediate proteasomal degradation of substrate proteins. Neddylation involves the covalent attachment of NEDD8 to target proteins, primarily Cullins, enhancing CRL complex assembly and enzymatic activity. Dysregulation of NEDD8 signaling is implicated in cancer, neurodegenerative diseases, and immune disorders, making it a therapeutic target of interest.
Recombinant NEDD8 proteins are engineered using expression systems like *E. coli* or mammalian cells to ensure high purity and bioactivity. These proteins retain the conserved ubiquitin-like fold and C-terminal diglycine motif required for conjugation. Recombinant NEDD8 enables in vitro studies of neddylation mechanisms, including interactions with E1 (activating), E2 (conjugating), and E3 (ligase) enzymes, as well as de-neddylation processes mediated by the COP9 signalosome. They are essential tools for screening inhibitors (e.g., MLN4924/Pevonedistat, a NEDD8-activating enzyme inhibitor in clinical trials) or developing assays to study CRL-dependent substrate turnover.
Additionally, recombinant NEDD8 facilitates structural studies (e.g., X-ray crystallography, NMR) to resolve molecular interactions and dynamics. Its applications extend to understanding pathological conditions linked to aberrant protein degradation, such as tumorigenesis, and exploring targeted therapies. The development of recombinant NEDD8 underscores its importance in both basic research and drug discovery, offering insights into cellular regulation and therapeutic intervention strategies.
×
